Format

Send to

Choose Destination
AAPS J. 2005 Oct 5;7(2):E467-74.

Evidence of effectiveness: how much can we extrapolate from existing studies?

Author information

1
Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA 15219, USA. leehwd@yahoo.com

Abstract

Drug development can be a science of extrapolation if the use of a drug exposure-response relationship is embraced and implemented through mechanistically oriented pharmacokinetic (PK)-pharmacodynamic (PD) modeling analysis and clinical trial simulation. The traditional requirement of at least 2 adequate and well-controlled phase III studies by the US Food and Drug Administration for drug approval can be waived in certain situations, substantially reducing the resources and time. In this article, the authors introduce a real drug development case where the chance for this exemption was maximized by actively using PK-PD modeling followed by clinical trial simulation, resulting in faster and more economical introduction of a new dosage regimen to patients.

PMID:
16353924
PMCID:
PMC2750984
DOI:
10.1208/aapsj070247
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center